Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | President, Worldwide R&D | September 13, 2024 | September 17, 2024 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | Director | January 20, 2023 | January 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date September 13, 2024 · Filed September 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,074 |
Ending reported balance
After 2024-09-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-30 · Grant · Acquired 300 · Balance 197,172 F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Row 2 · 2024-09-13 · Tax withholding · Disposed 12,098 · Balance 185,074 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
Mirati Therapeutics, Inc.
Report date January 20, 2023 · Filed January 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,465 |
Reported balance
After 2023-01-20 transaction · row 1
1 source rowRow 1 · 2023-01-20 · Grant · Acquired 4,444 · Balance 10,465 F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. |
| Non Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 7,520 |
Reported balance
After 2023-01-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-20 · Grant · Acquired 7,520 · Balance 7,520 F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date.
F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-11-08 · Disposition to issuer · Disposed 6,878 · Balance 955 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $189,150 and 3,098 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. Row 2 · 2019-11-08 · Disposition to issuer · Disposed 955 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.01 · Expires 2026-06-12 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,981 and 2,751 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.53 · Expires 2027-06-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.72 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.41 · Expires 2029-06-14 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-08 · Disposition to issuer · Disposed 6,583 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $189,150 and 3,098 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,981 and 2,751 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2018 Filed Apr 3, 2018 20:32 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 319 | $31.29 | $9,981.51 |
DisclosureSEC source: 0001209191-18-023363 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,837 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 23:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 5,812 | $81.36 | $472,864.32 |
DisclosureSEC source: 0001140361-18-015075 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,676 Read SEC document |
| March 22, 2018 Filed Apr 27, 2018 23:23 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 5,835 | $81.36 | $474,735.60 |
DisclosureSEC source: 0001140361-18-020301 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,653 F1 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of shares reported as forfeited. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 51,300 | $0.00 Strike: $83.57 | $0.00 |
DisclosureSEC source: 0001140361-18-014190 · doc1.xml · derivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,300 Underlying: Common Stock · 51,300 shares Expires 2028-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 16,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-014190 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,488 F1 · price: Restricted stock units granted on March 15, 2018. Price not applicable. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,861 | $83.57 | $406,233.77 |
DisclosureSEC source: 0001140361-18-014190 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,448 Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 01:44 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,576 | $79.86 | $205,719.36 |
DisclosureSEC source: 0001140361-18-012368 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,309 Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 02:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 20,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011010 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,885 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. Read SEC document |
| February 26, 2018 Filed Apr 27, 2018 00:30 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 20,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-019854 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,024 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. F4 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of RSUs reported as earned. Read SEC document |
| January 18, 2018 Filed Jan 22, 2018 18:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001214659-18-000584 · marketforms-40823.xml · derivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-01-17 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 10,000 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001140361-18-000914 · doc1.xml · derivative · entry 5 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,331 Underlying: Common Stock · 10,000 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 5,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001140361-18-000914 · doc1.xml · derivative · entry 4 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,225 Underlying: Common Stock · 5,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,000 | $89.23 | $1,338,400.50 |
DisclosureSEC source: 0001140361-18-000914 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,976 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $88.84 to $90.00. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $37.46 | $374,600.00 |
DisclosureSEC source: 0001140361-18-000914 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 5,000 | $26.49 | $132,450.00 |
DisclosureSEC source: 0001140361-18-000914 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F2 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) exclude 1,435 shares as previously reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 1,011 shares inadvertently included in prior reports based on a reconciliation with the Company's records. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 18:22 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 292 | $34.20 | $9,986.40 |
DisclosureSEC source: 0001209191-18-001280 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,518 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| October 01, 2017 Filed Oct 3, 2017 18:17 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 311 | $32.09 | $9,979.99 |
DisclosureSEC source: 0001209191-17-055386 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,226 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy) Common Stock · Derivative | 10,000 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001140361-17-035899 · doc1.xml · derivative · entry 5 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,934 Underlying: Common Stock · 10,000 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy) Common Stock · Derivative | 5,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001140361-17-035899 · doc1.xml · derivative · entry 4 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,225 Underlying: Common Stock · 5,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,000 | $90.50 | $1,357,500.00 |
DisclosureSEC source: 0001140361-17-035899 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,422 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $89.26 to $91.89. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $37.46 | $374,600.00 |
DisclosureSEC source: 0001140361-17-035899 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 5,000 | $26.49 | $132,450.00 |
DisclosureSEC source: 0001140361-17-035899 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. Read SEC document |
| July 06, 2017 Filed Feb 15, 2018 01:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 415 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008543 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,561 F1 · date: On July 6, 2017, the reporting person gifted 415 shares to an educational institution. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 19:04 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 307 | $32.55 | $9,992.85 |
DisclosureSEC source: 0001209191-17-043734 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,915 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy) Common Stock · Derivative | 603 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001140361-17-025625 · doc1.xml · derivative · entry 9 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,331 Underlying: Common Stock · 603 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 603 | $90.00 | $54,270.00 |
DisclosureSEC source: 0001140361-17-025625 · doc1.xml · nonDerivative · entry 6 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,422 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F2 · price: All shares sold at the same price. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 603 | $37.46 | $22,588.38 |
DisclosureSEC source: 0001140361-17-025625 · doc1.xml · nonDerivative · entry 5 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy) Common Stock · Derivative | 9,397 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001140361-17-025625 · doc1.xml · derivative · entry 8 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,934 Underlying: Common Stock · 9,397 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy) Common Stock · Derivative | 5,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001140361-17-025625 · doc1.xml · derivative · entry 7 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,225 Underlying: Common Stock · 5,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 9,397 | $90.00 | $845,730.00 |
DisclosureSEC source: 0001140361-17-025625 · doc1.xml · nonDerivative · entry 4 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,422 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F2 · price: All shares sold at the same price. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $90.00 | $450,000.00 |
DisclosureSEC source: 0001140361-17-025625 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,819 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F2 · price: All shares sold at the same price. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 9,397 | $37.46 | $352,011.62 |
DisclosureSEC source: 0001140361-17-025625 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 5,000 | $26.49 | $132,450.00 |
DisclosureSEC source: 0001140361-17-025625 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 20:36 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $31.53 | $0.00 |
DisclosureSEC source: 0001209191-17-041148 · doc4.xml · derivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-16 F1 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the initial annual grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option becomes fully vested in the event of a change in control of the Company. Read SEC document |
| June 02, 2017 Filed Jun 7, 2017 00:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,036 | $90.72 | $184,705.92 |
DisclosureSEC source: 0001140361-17-024246 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,422 Read SEC document |
| May 17, 2017 Filed May 19, 2017 18:05 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001190725-17-000127 · edgardoc.xml · derivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,036 | $91.50 | $186,294.00 |
DisclosureSEC source: 0001140361-17-021239 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,458 Read SEC document |
| April 28, 2017 Filed May 17, 2017 22:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 302 | $70.30 | $21,231.81 |
DisclosureSEC source: 0001140361-17-021239 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,494 F1 · date: Represents shares acquired by the reporting person pursuant to issuer's Employee Stock Purchase Plan. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 17:28 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 317 | $31.49 | $9,982.33 |
DisclosureSEC source: 0001209191-17-025143 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,608 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 64,030 | $0.00 Strike: $87.42 | $0.00 |
DisclosureSEC source: 0001140361-17-013319 · doc1.xml · derivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,030 Underlying: Common Stock · 64,030 shares Expires 2027-03-21 F2 · derivative.exercise_date: Option grant vests 12/48th on March 22, 2018 and 1/48th on the 22nd day of each month thereafter. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 19,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-013319 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,192 F1 · price: Restricted stock units granted on March 22, 2017. Price not applicable. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 5,116 | $92.50 | $473,230.00 |
DisclosureSEC source: 0001140361-17-012653 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,402 Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 23:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,924 | $93.95 | $274,709.80 |
DisclosureSEC source: 0001140361-17-010930 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,518 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001140361-17-009668 · doc1.xml · derivative · entry 4 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,225 Underlying: Common Stock · 15,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: Trade made pursuant to a 10b5-1 plan executed on May 12, 2016. F6 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,000 | $87.99 | $1,319,850.00 |
DisclosureSEC source: 0001140361-17-009668 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,442 F4 · date: Trade made pursuant to a 10b5-1 plan executed on May 12, 2016. F5 · price: All shares were sold at the same price. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,000 | $26.49 | $397,350.00 |
DisclosureSEC source: 0001140361-17-009668 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: Trade made pursuant to a 10b5-1 plan executed on May 12, 2016. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 14,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-009668 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,442 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2017, 2018 and 2019, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the fiscal year ended December 31, 2016, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 19:18 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 340 | $29.39 | $9,992.60 |
DisclosureSEC source: 0001209191-17-001507 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,291 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| November 25, 2016 Filed Nov 30, 2016 01:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001140361-16-088121 · doc1.xml · derivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,225 Underlying: Common Stock · 15,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 12, 2016. F3 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| November 25, 2016 Filed Nov 30, 2016 01:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,000 | $87.40 | $1,310,988.00 |
DisclosureSEC source: 0001140361-16-088121 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,878 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 12, 2016. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $86.67 to $88.06. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.